Evolus (EOLS) Competitors $9.48 -0.25 (-2.57%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$9.45 -0.03 (-0.32%) As of 07/11/2025 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EOLS vs. GMTX, IBRX, TWST, ARWR, APLS, VCEL, RXRX, NAMS, DNLI, and KNSAShould you be buying Evolus stock or one of its competitors? The main competitors of Evolus include Gemini Therapeutics (GMTX), ImmunityBio (IBRX), Twist Bioscience (TWST), Arrowhead Pharmaceuticals (ARWR), Apellis Pharmaceuticals (APLS), Vericel (VCEL), Recursion Pharmaceuticals (RXRX), NewAmsterdam Pharma (NAMS), Denali Therapeutics (DNLI), and Kiniksa Pharmaceuticals International (KNSA). These companies are all part of the "pharmaceutical products" industry. Evolus vs. Its Competitors Gemini Therapeutics ImmunityBio Twist Bioscience Arrowhead Pharmaceuticals Apellis Pharmaceuticals Vericel Recursion Pharmaceuticals NewAmsterdam Pharma Denali Therapeutics Kiniksa Pharmaceuticals International Evolus (NASDAQ:EOLS) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk. Which has more risk & volatility, EOLS or GMTX? Evolus has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500. Do analysts recommend EOLS or GMTX? Evolus presently has a consensus target price of $23.75, suggesting a potential upside of 150.53%. Given Evolus' stronger consensus rating and higher probable upside, research analysts clearly believe Evolus is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evolus 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals hold more shares of EOLS or GMTX? 90.7% of Evolus shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 5.9% of Evolus shares are held by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has higher valuation and earnings, EOLS or GMTX? Evolus has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvolus$266.27M2.30-$50.42M-$0.89-10.65Gemini TherapeuticsN/AN/A-$71.87M-$1.00-56.91 Is EOLS or GMTX more profitable? Gemini Therapeutics has a net margin of 0.00% compared to Evolus' net margin of -20.40%. Gemini Therapeutics' return on equity of -38.78% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Evolus-20.40% -759.04% -20.14% Gemini Therapeutics N/A -38.78%-35.88% Does the media refer more to EOLS or GMTX? In the previous week, Evolus had 3 more articles in the media than Gemini Therapeutics. MarketBeat recorded 3 mentions for Evolus and 0 mentions for Gemini Therapeutics. Evolus' average media sentiment score of 0.52 beat Gemini Therapeutics' score of 0.00 indicating that Evolus is being referred to more favorably in the media. Company Overall Sentiment Evolus Positive Gemini Therapeutics Neutral SummaryEvolus beats Gemini Therapeutics on 12 of the 15 factors compared between the two stocks. Get Evolus News Delivered to You Automatically Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EOLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EOLS vs. The Competition Export to ExcelMetricEvolusMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$611.23M$10.56B$5.56B$9.11BDividend YieldN/A2.08%5.06%4.01%P/E Ratio-10.6516.8328.2320.27Price / Sales2.3030.16434.20100.92Price / CashN/A22.5637.1257.67Price / Book105.333.668.045.49Net Income-$50.42M$235.43M$3.19B$250.45M7 Day Performance2.27%1.27%3.62%4.78%1 Month Performance-4.53%5.34%5.98%9.58%1 Year Performance-19.46%-15.78%29.39%16.41% Evolus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EOLSEvolus3.911 of 5 stars$9.48-2.6%$23.75+150.5%-19.5%$611.23M$266.27M-10.65170GMTXGemini TherapeuticsN/A$54.50+0.7%N/A+21.3%$2.36BN/A-54.5030High Trading VolumeIBRXImmunityBio2.3637 of 5 stars$2.64-2.2%$12.25+364.0%-57.6%$2.33B$14.74M-4.55590News CoverageAnalyst ForecastTWSTTwist Bioscience4.3843 of 5 stars$36.79+2.4%$50.40+37.0%-28.8%$2.20B$312.97M-11.32990Gap DownARWRArrowhead Pharmaceuticals3.5866 of 5 stars$15.80-1.7%$43.71+176.7%-34.9%$2.18B$3.55M-11.29400APLSApellis Pharmaceuticals4.1683 of 5 stars$17.31-0.7%$40.05+131.4%-50.8%$2.18B$781.37M-9.67770VCELVericel3.5498 of 5 stars$42.55+2.0%$61.14+43.7%-17.7%$2.14B$237.22M1,418.81300RXRXRecursion Pharmaceuticals1.9991 of 5 stars$5.06+0.6%$7.00+38.3%-36.8%$2.06B$58.84M-2.86400Analyst ForecastOptions VolumeGap DownNAMSNewAmsterdam Pharma2.706 of 5 stars$18.11-2.5%$42.89+136.8%+8.4%$2.03B$45.56M-9.634Positive NewsDNLIDenali Therapeutics4.6406 of 5 stars$13.99-0.8%$33.71+141.0%-36.5%$2.03BN/A-5.24430News CoverageInsider TradeAnalyst RevisionKNSAKiniksa Pharmaceuticals International3.5358 of 5 stars$27.67-1.3%$38.80+40.2%+32.4%$2.02B$423.24M-110.68220Analyst Forecast Related Companies and Tools Related Companies Gemini Therapeutics Competitors ImmunityBio Competitors Twist Bioscience Competitors Arrowhead Pharmaceuticals Competitors Apellis Pharmaceuticals Competitors Vericel Competitors Recursion Pharmaceuticals Competitors NewAmsterdam Pharma Competitors Denali Therapeutics Competitors Kiniksa Pharmaceuticals International Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EOLS) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evolus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EOLS Stock Alerts